Our results indicate that by decreasing the MDR1, MRP1, and ABCG2 drug transporters, AR inhibitor fidarestat increases the sensitivity of DOX to colon cancer by decreasing the efflux of drugs from the cells. The gene discussed is ABCC1; the disease is malignant colon neoplasm.